COVID-19: Still Poorly Understood

share Share

During the first few months of the coronavirus disease, it was being suggested that severe COVID-19 may represent a hyperimmune disorder, similar to secondary haemophagocytic lymphohistiocytosis (sHLH) and macrophage activation syndrome (MAS). Cytokine storm, elevated plasma levels, ferritin and inflammatory biomarkers are all typical signs of sHLH/MAS. But in many severe cases, T cells were found to be decreased, indicating T cell lymphopaenia may also be a prognostic marker to be considered when monitoring COVID-19 patients. sHLH occurs in around 4.3% of sepsis cases, and in COVID-19 patients with massive hyperinflammation, a diagnosis of sHLH/MAS may be appropriate.

 

More recently, COVID-19 has been compared with sepsis. Severe COVID-19 may represent a novel form of viral sepsis characterised by T cell deficiencies, systemic hyperinflammation and COVID-19-associated coagulopathy. However, there is a need for more investigation to understand the relationships between these clinical features and organ failure.

 

COVID-19 offers different clinical pictures in different patients, ranging from asymptomatic or mild infections in children and young adults to lethal sepsis-like illness in elderly patients. In younger patients, T cell immunity is more pronounced and active, which could explain the mild impact, but in the elderly, there is a decline in T cell functions, which could possibly be the reason for this condition often turning into a life-threatening disease.

 

With all these different clinical manifestations, it is important to develop a greater understanding of coronavirus disease. From hyperinflammatory features observed in sepsis, sHLH/MAS, and cytokine release syndrome to impaired T cell function, what is the common ground and which areas need to be targeted when determining an effective treatment approach? If we apply the effect T cells have in children and young adults, it might be possible to treat the disease by a reversal of T cell impairment, which would improve viral clearance and allow faster control of the infection.

 

SARS-COV-2 is a new pathogen with a sepsis-like manifestation. Its clinical characteristics, including hyperinflammation, T cell deficiencies, coagulation abnormalities, and organ dysfunction, are consistent with a diagnosis of viral sepsis, but there is still a need for more clarity so that effective treatment approaches can be developed and patient outcomes can improve.


Source: Critical Care

Image Credit: iStock


«« Better Planning of COVID-19 Vaccine Trials


Corticosteroids and Mortality in COVID-19 Patients »»

References:

Riva G, Nasillo V, Tagliafico E et al. (2020) COVID-19: more than a cytokine storm. Crit Care 24, 549. doi.org/10.1186/s13054-020-03267-w

Published on : Fri, 2 Oct 2020



Related Articles

The world is desperate for a reliable vaccine against COVID-19. However, the pressure for such rapid introduction could lead... Read more

The coronavirus disease has spread throughout the world and has resulted in many challenges for healthcare systems. It is a new disease... Read more

The economic and clinical fragilities of healthcare systems around the globe have never been more visible than during the COVID-19... Read more

Sepsis, Coronavirus, COVID-19, hyperinflammation, T cells COVID-19: Still Poorly Understood

No comment


Please login to leave a comment...

Highlighted Products